Shares of Invitae NVTA fell in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were unchanged 0.00% over the past year to ($0.63), which missed the estimate of ($0.55).
Revenue of $100,431,000 rose by 51.51% from the same period last year, which beat the estimate of $98,400,000.
Outlook
Invitae Sees FY2021 Revs Exceeding $450M
Conference Call Details
Date: Feb 17, 2021
Time: 04:30 PM
ET Webcast URL: https://www.directeventreg.com/der/toRegistration.action
Recent Stock Performance
Company's 52-week high was at $61.59
Company's 52-week low was at $7.42
Price action over last quarter: Up 6.93%
Company Description
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
